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Treatment Outcome and Mortality among Patients with 
Multidrug-resistant Tuberculosis in Tuberculosis Hospitals of the 
Public Sector
This study was conducted to evaluate treatment outcome, mortality, and predictors of 
both in patients with multidrug-resistant tuberculosis (MDR-TB) at 3 TB referral hospitals in 
the public sector of Korea. We included MDR-TB patients treated at 3 TB referral hospitals 
in 2004 and reviewed retrospectively their medical records and mortality data. Of 202 
MDR-TB patients, 75 (37.1%) had treatment success and 127 (62.9%) poor outcomes. 
Default rate was high (37.1%, 75/202), comprising 59.1% of poor outcomes. Male sex 
(adjusted odds ratio [aOR], 2.91; 95% confidence interval [CI], 1.13-7.49), positive smear 
at treatment initiation (aOR, 5.50; 95% CI, 1.22-24.90), and extensively drug-resistant TB 
(aOR, 10.72; 95% CI, 1.23-93.64) were independent predictors of poor outcome. The all-
cause mortality rate was 31.2% (63/202) during the 3-4 yr after treatment initiation. In 
conclusion, the treatment outcomes of patients with MDR-TB at the 3 TB hospitals are 
poor, which may reflect the current status of MDR-TB in the public sector of Korea. A 
more comprehensive program against MDR-TB needs to be integrated into the National 
Tuberculosis Program of Korea.
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INTRODUCTION
Multidrug-resistant tuberculosis (MDR-TB) is a major challenge 
for TB control worldwide. Treatment of MDR-TB is difficult be-
cause MDR-TB entails higher cost, longer treatment period, and 
more adverse events than drug-sensitive TB (1, 2). Therefore, a 
comprehensive control program is essential for MDR-TB. The 
World Health Organization (WHO) has recommended that the 
surveillance and management of MDR-TB should be included 
in the National Tuberculosis Program (NTP) (3). 
  Korea has a complex TB control system, and the private sec-
tor has played a greater role than the public sector in the treat-
ment of TB. In 2008, the notification rate of TB was 77.8% in the 
private sector and 22.2% in the public sector (4). Since the NTP 
of Korea has focused on new patients, few data have been report-
ed on the nationwide status of MDR-TB. 
  In Korea, most MDR-TB patients are treated in 1) the 3 TB re-
ferral hospitals in the public sector, 2) the 76 university or tertia-
ry-care hospitals in the private sector, or 3) the 9 Korean Nation-
al Tuberculosis Association (KNTA) chest clinics, which are con-
sidered to be mixed sector (5, 6). The 3 TB hospitals have been 
responsible for the management of MDR-TB in the public sec-
tor of Korea. 
  The aim of this study was to evaluate treatment outcomes, 
mortality and predictors of both in MDR-TB patients at the 3 TB 
hospitals in the public sector of Korea. 
METERALS AND METHODS
Study subjects and data collection
Patients diagnosed with MDR-TB and treated at 3 TB hospitals 
(National Mokpo Tuberculosis Hospital, Mokpo, National Ma-
san Tuberculosis Hospital, Masan, and Seobuk Hospital, Seoul, 
Korea) between January 1 and December 31, 2004 were includ-
ed. We reviewed their medical records, radiographic findings, 
and mortality data retrospectively. If patient was treated for sev-Jeon DS, et al.  •  MDR-TB in the Public Sector of Korea
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eral times, we analyzed the outcome of the first treatment. Mor-
tality data were collected from medical records up to December 
31, 2008, or by inquiries made to the Korean National Statistical 
Office up to December 31, 2007. 
Definitions
MDR-TB is defined as TB resistant to at least isoniazid (INH) 
and rifampicin (RFP). Extensively drug-resistant TB (XDR-TB) 
is defined as TB resistant to at least INH and RFP plus any fluo-
roquinolones and at least one of the injectable second-line drugs 
(amikacin, kanamycin, or capreomycin) (7).
  The patients were classified into the following 3 groups accord-
ing to their TB treatment history: 1) new patients with no histo-
ry of TB treatment, 2) patients previously treated with first-line 
drugs only, or 3) patients previously treated with second-line 
drugs. Treatment history was defined as treatment with anti-TB 
drugs for ≥ 30 days. 
  ‘Used drug’ was defined as a drug that was used for > 3 months. 
‘Drug with unknown-susceptibility’ was defined as a drug used 
for TB treatment but without drug susceptibility test (DST) (ca-
preomycin, clarithromycin, roxithromycin, amoxicillin-clavu-
linate, linezolid, interferon-gamma, moxifloxacin and gatifloxa-
cin).
  Treatment outcomes were classified according to the WHO’s 
recommended 6 criteria (3) plus “short-term treatment comple-
tion” . The duration of adequate treatment was defined as ≥ 18 
months, including ≥ 12 months after culture conversion. The 
definition of short-term treatment completion was applied to 
patients who met all these criteria (6): 1) inadequate treatment 
duration, but more than 6 months; 2) more than 3 consecutive 
negative cultures before treatment completion; and 3) treatment 
completion by a doctor based on favorable treatment response. 
“Treatment success” was defined as cure, treatment completion 
and short-term treatment completion. “Poor outcome” was de-
fined as treatment failure, death during treatment, default and 
transfer out. Patients who interrupted their treatment for ≥ 2 con-
secutive months were defined as defaulters. Chest radiograph 
at the time of treatment initiation was categorized based on the 
National Tuberculosis Association classification (8). 
Treatment of MDR-TB patients
The treatment regimen was individualized based on the most 
recent DST result and the history of drugs taken by each patient. 
Injectable agents were typically used for 6 to 7 months. The an-
ti-tuberculosis agents were self-administered except injectable 
agents during hospitalization. The total treatment duration was 
a minimum of 18 months after culture conversion. Surgical re-
section was considered for patients with localized cavitary le-
sions and anticipated adequate postoperative lung function, 
and for selected patients with bilateral lesions if medical treat-
ment had failed or was expected to fail.
Drug susceptibility test
  DSTs were performed at each hospital using the absolute con-
centration method. Pyrazinamide resistance was determined 
by pyrazinamidase test in all 3 hospitals.
Statistical analysis
The chi-square test or Fisher’s exact test was performed to com-
pare categorical variables, and Student’s t-test or analysis of vari-
ance was performed to compare continuous variables. To iden-
tify the predictors of poor outcome, we compared variables be-
tween treatment success and poor outcome by univariate anal-
ysis. Binary logistic regression analysis with backward elimina-
tion method was performed for variables with P < 0.2 in the uni-
variate analysis, and the Hosmer-Lemeshow test was used for 
testing the goodness-of-fit of the models. The Kaplan-Meier 
method was used for survival analysis, the log-rank test was 
performed to compare the survival rates between the groups, 
and Cox regression analysis was performed to identify risk fac-
tors associated with mortality. All analysis were performed us-
ing SPSS version 15.0 (SPSS Inc, Chicago, IL, USA), and the re-
sults with P < 0.05 were considered statistically significant. 
Ethics statement
The protocol for this study was approved by the institutional re-
view board of the National Masan Tuberculosis Hospital (IRB 
approval number: IRB-08-N02), and informed consent was 
waved.
RESULTS
Baseline demographic and clinical characteristics 
In total, 202 patients were included in this study, 46 (23%) from 
the Seobuk Hospital, 39 (19%) from the National Mokpo Tuber-
culosis Hospital, and 117 (58%) from the National Masan Tuber-
culosis Hospital. The mean age was 44.8 (median, 43; range, 16-
96) yr and 156 (77.2%) were male (Table 1). HIV-ELISA tests were 
performed on 2 patients and all were sero-negative. Of 202 pa-
tients, 79 (39.1%) had at least 1 comorbidity. Diabetes mellitus 
was the most common (n = 38, 18.8%), followed by chronic liver 
disease (n = 12, 5.9%), cardiovascular disease (n = 10, 5.0%), al-
cohol dependence (n = 9, 4.5%), and psychiatric disease (n = 9, 
4.5%).
  When patients were categorized on the basis of their previous 
treatment histories: 41 (21.3%) were new patients, 88 (43.6%) 
had been treated previously with first-line drugs only, and 73 
(36.1%) had been treated previously with second-line drugs. 
Most of patients were transferred from private clinics and gen-
eral hospitals (37.6%), public health centers (24.8%), tertiary hos-
pitals (8.9%), and the KNTA chest clinics (8.9%). 
  A mean of 4.7 (range, 2-9) of 10 tested drugs showed resis-
tance. The baseline resistance patterns are shown in Fig. 1. At Jeon DS, et al.  •  MDR-TB in the Public Sector of Korea
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treatment initiation, 179 (88.6%) patients had smear-positive 
sputum. Chest radiograph at the time of treatment initiation 
showed that 70.1% (141/201) of the patients had far advanced 
disease, 89.1% (179/201) bilateral disease, 65.2% (131/201) a cav-
ity, and 32.8% (66/201) bilateral cavities. 
Treatment modality
Treatment regimen included a mean of 4.9 drugs (median 5, 
range 3-7), of which a mean of 3.6 drugs (median 4, range 0-7) 
were active by DST. A mean of 0.2 (median 0, range 0-3) ‘drugs 
with unknown-susceptibility’ were administered to 29 (14.4%) 
patients. Injectable agents were administered to 140 (69.3%) 
patients; streptomycin 85 (60.7%), kanamycin 54 (38.6%), and 
amikacin 1 (0.7%). Surgical resection was performed on 8 (4%) 
patients. At treatment initiation, 154 (76.2%) patients were hos-
pitalized. 
Table 1. Baseline characteristics of 202 patients with multidrug-resistant tuberculosis 
Characters Non-XDR-TB (n = 175)   XDR-TB (n = 27)   Total (n = 202) P
Demographics
   Age, years, mean ± SD (range)
   Male
   Body mass index, mean ± SD (n = 162)
   Family history of TB
   DM
  45.1 ± 15.0
 135 (77.1)
18.8 ± 3.2
55/165 (33.3)
   32 (18.3)
  42.5 ± 12.3
   21 (77.3)
18.7 ± 3.7
15/25 (60.0)
     6 (22.2)
  44.8 ± 14.7
156 (77.2)
18.8 ± 3.2
  70 (34.7)
  38 (18.8)
0.397
1.000
0.990
0.014
0.790
History of previous TB treatment
   Never treated
   First-line drugs only
   Second-line drugs
   34 (19.4)
   85 (48.6)
56 (32)
     7 (25.9)
     3 (11.1)
17 (63)
  41 (20.3)
  88 (43.6)
  73 (36.1)
0.445
< 0.001
0.003
Previous surgery    1 (0.6)    1 (3.7)   2 (1.0) 0.250
Resistant drugs, mean ± SD (range) 4.4 ± 1.6 (2-9) 7.1 ± 1.3 (4-9) 4.7 ± 1.8 (2-9) < 0.001
Smear positive  155 (88.6)    24 (88.9) 179 (88.6) 1.000
Extra-pulmonary involvement  13 (7.4) 0 13 (6.4) 0.223
Chest radiograph findings (n = 201)
   Severity
       Far advanced
       Moderate advanced
       Minimal
   Extent, Bilateral
   Cavity, yes
   Cavity, bilateral
 122 (70.1)
   42 (24.1)
 10 (5.7)
 155 (89.1)
 115 (66.1)
   61 (35.1)
   19 (70.4)
     8 (29.6)
0
   24 (88.9)
   16 (59.3)
     6 (22.0)
141 (70.1)
  50 (24.9)
10 (5.0)
179 (89.1)
131 (65.2)
66 (32.8)
1.000
0.632
0.364
1.000
0.519
0.272
Data are presented as number (%) of patients unless otherwise specified. TB, tuberculosis; XDR-TB, extensively drug-resistant tuberculosis.
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Fig. 1. Baseline drug resistance among 202 patients with multidrug-resistant tuber-
culosis. INH, isoniazid; RFP, rifampicin; EMB, ethambutol; PZA, pyrazinamide; SM, 
streptomycin; KM, kanamycin; OFX, ofloxacin; PAS, para-aminosalicylic acid; PTH, 
prothionamide; CS, cycloserine.
Table 2. Treatment outcomes of 202 patients with multidrug-resistant tuberculosis according to previous treatment history
Outcomes Never treated First-line drugs only Second-line drugs   Total P
Treatment success
   Cure
   Treatment completion
   Short-term treatment completion
 22 (53.7)
 13 (31.7)
 2 (4.9)
   7 (17.1)
 38 (43.2)
 23 (26.1)
 11 (12.5)
 4 (4.5)
 15 (20.5)
 10 (13.7)
 4 (5.5)
 1 (1.4)
   75 (37.1)
   46 (22.8)
 17 (8.4)
 12 (5.9)
0.000
0.049
0.231
0.004
Poor outcome
   Treatment failure
   Transfer out
   Default
   Death 
 19 (46.3)
 1 (2.4)
 4 (9.8)
 14 (34.1)
0
 50 (56.8)
 1 (1.1)
 20 (22.7)
 27 (30.7)
 2 (2.3)
 58 (79.5)
 1 (1.4)
 16 (21.9)
 34 (46.6)
 7 (9.6)
 127 (62.9)
   3 (1.5)
   40 (19.8)
   75 (37.1)
   9 (4.5)
0.000
0.794
0.191
0.111
0.045
Total 41 (100) 88 (100) 73 (100) 202 (100)
Data are presented as number (%) of patients.Jeon DS, et al.  •  MDR-TB in the Public Sector of Korea
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Treatment outcomes and predictors of poor outcome 
Among 202 patients, 46 (22.8%) were cured, 17 (8.4%) complet-
ed treatment, and 12 (5.9%) completed short-term treatment: 
therefore, a total of 75 (37.1%) were classified into treatment suc-
cess (Table 2). The treatment success rate was significantly low-
er in patients treated with second-line drugs (20.5%, 12/73) than 
in new patients (53.7%, 22/41; P < 0.001) and patients treated 
with first-line drugs only (43.2%, 38/88; P = 0.003). 
  Among 202 patients, 127 (62.9%) had poor outcome; 75 (37.1 
%) defaulted, 3 (1.5%) failed their treatment, 40 (19.8%) were 
transferred, and 9 (4.5%) died during treatment. Among the 75 
patients who defaulted, 46 (61.3%) were culture positive at the 
time of treatment interruption and treatment was reinitiated in 
12 patients during the study period at the 3 hospitals. Among 
Table 3. Predictors of poor outcome among 202 patients with multidrug-resistant tuberculosis
Predictors
Treatment success  
(n = 75)
Poor outcome  
(n = 127)
Univariate analysis Multivariate analysis
OR* (95% CI) P aOR* (95% CI) P
Baseline characteristics
   Age, years, mean ± SD
   Male (mean ± SD)
   BMI, mean ± SD (n = 162)
   Smoker
   Alcohol abuse
   Family history of TB
   Underlying disease
   Diabetes
    43.8±15.24
     51 (68.8)
19.3±3.7
41/74 (55.4)
     21 (28.0)
24/72 (33.3)
     47 (62.7)
     15 (20.0)
  45.3±14.3
105 (82.7)
18.5±2.9
  87/121 (71.9)
  47 (37.0)
  46/118 (62.1)
  76 (59.8)
  23 (18.1)
  1.01 (0.99-1.03)
  2.25 (1.15-4.82)
  0.93 (0.84-1.03)
  2.06 (1.12-3.78)
  1.51 (0.81-2.81)
  1.28 (0.69-2.36)
  0.89 (0.49-1.60)
  0.89 (0.43-1.83)
0.48
0.023
0.152
0.021
0.219
0.444
0.766
0.852
2.91 (1.13-7.49) 0.026
Previous TB history
   Anti-TB treatment
   Anti-MDR-TB treatment
   TB surgery
     53 (70.7)
     15 (20.0)
  0 (0)
108 (85.0)
  58 (45.7)
  2 (1.6)
  2.36 (1.18-4.73)
  3.36 (1.73-6.54)
NA
0.018
< 0.001
0.531
2.15 (0.89-5.19) 0.089
Drug resistance
      to ethambutol
      to pyrazinamide
      to streptomycin
      to kanamycin
      to prothionamide
      to para-aminosalicylic acid
      to cycloserine
      to ofloxacin
   No. of resistant drugs (mean ± SD)
   XDR-TB
     48 (64.0)
     22 (29.3)
     30 (40.0)
     7 (9.3)
     11 (14.7)
     28 (37.3)
     4 (5.3)
     30 (40.0)
  4.4±1.6
     3 (4.0)
  86 (67.7)
  31 (24.4)
  47 (37.0)
  33 (26.0)
  33 (26.0)
  50 (39.4)
11 (8.7)
  66 (52.0)
  4.9±1.9
  24 (18.9)
  1.18 (0.65-2.15)
  0.78 (0.41-1.48)
  0.88 (0.49-1.58)
3.41 (1.42-8.7)
  2.04 (0.96-4.33)
  1.09 (0.61-1.96)
  1.68 (0.52-5.49)
  1.62 (0.91-2.89)
  1.16 (0.98-1.36)
    5.59 (1.62-19.28)
0.645
0.508
0.672
0.006
0.077
0.881
0.424
0.110
0.081
0.003
  4.56 (0.87-23.77)
10.72 (1.23-93.64)
0.072
0.032
Status at treatment initiation
   AFB smear positive
   Presence of symptoms
   Extra-pulmonary involvement
     62 (82.7)
     70 (93.3)
     7 (9.3)
117 (92.1)
118 (92.9)
  6 (4.7)
  2.45 (1.02-5.92)
  1.07 (0.34-3.31)
  0.48 (0.16-1.50)
0.064
0.91
0.24
  5.50 (1.22-24.90) 0.027
Chest radiograph findings (n = 201)
   Severity
       Minimal
       Moderate advanced
       Far advanced
   Extent, bilateral
   Cavity, yes
   Bilateral cavity
  8/75 (10.7)
21/75 (28.0)
46/75 (61.3)
63/75 (84.0)
49/75 (65.3)
19/75 (25.3)
  2/126 (1.6)
  29/126 (23.0)
  95/126 (75.4)
116/126 (92.1)
  82/126 (65.1)
  48/126 (38.1)
  0.14 (0.03-0.65)
  0.77 (0.40-1.48)
  1.93 (1.04-3.58)
  2.21 (0.90-5.40)
  1.01 (0.55-1.84)
  1.81 (0.96-3.41)
0.006
0.500
0.039
0.101
1.000
0.088
Laboratory findings (mean ± SD)
   Hemoglobin
   Total protein 
   Albumin
   Creatinine
   Cholesterol
   Hemoglobin
11.8±1.8
  7.2±0.7
  3.6±0.7
12.1±4.3
  1.0±1.2
150.2±34.2
11.9±2.0
  7.1±1.0
  3.5±0.7
11.5±5.9
  0.9±0.7
145.2±32.5
1.01 (0.87-1.18)
0.87 (0.61-1.24)
0.67 (0.42-1.07)
0.98 (0.93-1.04)
0.92 (0.67-1.25)
1.00 (0.99-1.01)
0.913
0.444
0.090
0.513
0.582
0.328
MDR-TB treatment
   Drugs in a regimen (mean ± SD)
       Total drugs
       Susceptible drugs
       Susceptible and unused drugs
       Drugs with unknown-susceptibility
   Adjunctive surgical treatment
   Admission at treatment initiation
  4.8±0.7
  3.6±1.4
  3.0±1.9
0.17±0.5
     3 (4.0)
     56 (74.7)
  4.9±0.7
  3.6±1.4
  2.5±2.0
  0.2±0.5
  5 (3.9)
  98 (77.2)
1.20 (0.81-1.78)
1.01 (0.89-1.24)
0.87 (0.75-1/02)
1.13 (0.64-1.97)
0.98 (0.23-4.24)
1.14 (0.59-2.23)
0.363
0.896
0.084
0.681
1.000
0.690
Data are presented as number (%) of patients unless otherwise specified; *Odds ratio for poor outcome. TB, tuberculosis;  MDR-TB, multidrug-resistant tuberculosis; XDR-TB, 
extensively drug-resistant tuberculosis.Jeon DS, et al.  •  MDR-TB in the Public Sector of Korea
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these 12 re-treated patients, 7 (58.3%) defaulted again, 2 (16.7%) 
were transferred out, and 1 (8.3%) was cured. Among the 40 trans-
ferred patients, 30 (75%) had positive culture at the time of trans-
fer. Mortality rate during treatment was higher in patients previ-
ously treated with second-line drugs (9.6%, 7/73) than in new 
patients (0%, 0/41; P = 0.048) and patients treated with first-line 
drugs only (2.3%, 2/88; P = 0.08).
  The results of univariate analysis for poor outcome are shown 
in Table 3. Male sex (adjusted odds ratio [aOR], 2.91; 95% confi-
dence interval [CI], 1.13-7.49; P = 0.026), positive smear at treat-
ment initiation (aOR, 5.50; 95% CI, 1.22-24.90; P = 0.027), and 
XDR-TB (aOR, 10.72; 95% CI, 1.23-93.64; P = 0.032) were inde-
pendent predictors of poor outcome. 
Table 4. Predictors of all-cause mortality among patients with multidrug-resistant tuberculosis
Predictors
Survivor  
(n = 139)
Non-survivor  
(n = 63)
Univariate analysis Multivariate analysis
HR* (95% CI) P  aHR* (95% CI) P 
Baseline chracteristics
   Age (yr)
   Male
   BMI (n = 162)
   Smoker 
   Alcohol abuse
   Familly history of TB
   Underlying disease
   Diabetes
  42.1±13.5
    102 (73.4)
19.3±3.0
  83/134 (61.9)
  46/134 (34.3)
  45/130 (34.6)
      90 (64.7)
      26 (18.7)
  50.6±15.6
54 (85.7)
17.6±3.4
45/61 (73.8)
22/61 (36.1)
25/60 (41.7)
33 (52.4)
12 (19.0)
1.03 (1.02-1.05)
2.18 (0.98-4.84)
0.82 (0.74-0.92)
1.73 (0.89-3.37)
1.08 (0.57-2.03)
1.35 (0.72-2.53)
0.60 (3.33-1.10)
1.02 (0.48-2.19)
< 0.001
0.069
0.001
0.143
0.872
0.419
0.12
1.000
1.04 (1.01-1.07) 0.006
Previous TB history
   Anti-TB treatment
   Anti-MDR-TB treatment
   TB surgery
    102 (73.4)
      37 (26.6)
      1 (0.7)
59 (93.7)
36 (57.1)
1 (1.6)
  5.35 (1.82-15.76)
3.67 (1.97-6.87)
  2.23 (0.14-36.16)
0.001
< 0.001
1.000
2.21 (1.03-4.72) 0.041
Status at treatment initiation
   AFB smear positive
   Presence of symptoms
   Extra-pulmonary involvement
    119 (85.6)
    128 (92.1)
    10 (7.2)
60 (95.2)
60 (95.2)
3 (4.8)
  3.36 (0.96-11.76)
1.72 (0.46-6.39)
0.65 (0.17-2.43)
0.056
0.556
0.562
Drug resistance
      to ethambutol
      to pyrazinamide
      to streptomycin
      to kanamycin
      to prothionamide
      to para-aminosalicylic acid
      to cycloserine
      to ofloxacin
   No. of resistant drugs 
   XDR-TB
      89 (64.0)
      43 (30.9)
      57 (41.0)
      22 (15.8)
      24 (17.3)
      53 (38.1)
      9 (6.5)
      57 (41.0)
  4.6±1.7
    12 (8.6)
45 (71.4)
10 (15.9)
20 (31.7)
18 (28.6)
20 (31.7)
25 (39.7)
6 (9.5)
39 (61.9)
5.0±2.0
15 (23.8)
1.40 (0.74-2.68)
0.42 (0.20-0.91)
0.70 (0.36-1.26)
2.13 (1.04-4.33)
2.23 (1.12-4.44)
1.07 (0.58-1.96)
1.52 (0.52-4.47)
2.34 (1.27-4.31)
1.13 (0.99-1.29)
3.31 (1.44-7.57)
0.338
0.026
0.216
0.039
0.027
0.834
0.563
0.006
0.082
0.005
3.10 (1.05-9.11)
0.77 (0.57-1.04)
13.42 (2.98-60.53)
0.04
0.091
0.001
Chest radiograph findings (n = 201)
   Severity
       Minimal
       Moderate
       Far advanced
   Extent, bilateral
   Cavity, yes
   Bilateral cavity
  9/138 (6.5)
  46/138 (33.3)
  83/138 (60.1)
117/138 (84.8)
  82/138 (59.4)
  36/138 (26.1)
1/63 (1.6)
4/63 (6.3)
58/63 (92.1)
62/63 (98.4)
49/63 (77.8)
31/63 (49.2)
0.23 (0.03-1.87)
0.14 (0.05-0.40)
  7.69 (2.90-20.38)
11.13 (1.46-84.70)
2.39 (1.21-4.74)
2.75 (1.47-5.12)
0.176
< 0.001
< 0.001
0.006
0.016
0.002
  4.23 (1.33-13.47) 0.15
Laboratory findings (mean ± SD)
   Hemoglobin
   Total protein 
   Albumin
   Creatinine
  Cholesterol
12.0±2.1
  7.1±0.9
  3.6±0.6
  1.0±1.1
149.5±34.0
11.5±1.6
  7.1±0.9
  3.3±0.7
  0.8±0.3
142.2±31.1
0.90 (0.80-1.02)
0.96 (0.73-1.27)
0.54 (0.37-0.81)
0.54 (0.19-1.56)
0.99 (0.99-1.00)
0.086
0.769
0.002
0.255
0.137
0.84 (0.67-1.01) 0.068
MDR-TB treatment
   Drugs in a regimen (mean ± SD)
       Total drugs
       Susceptible drugs
       Susceptible and unused drugs
       Drugs with unknown-susceptibility
   Adjunctive surgical treatment
   Admission at treatment initiation
  4.9±0.8
  3.7±1.4
  2.9±1.9
  0.2±0.5
      7 (5.0)
   100 (71.9)
  4.9±0.7
  3.5±1.4
  2.1±1.9
  0.3±0.6
1 (1.6)
54 (85.7)
0.96 (0.69-1.33)
0.93 (0.79-1.10)
0.86 (0.75-0.99)
1.33 (0.90-1.95)
0.30 (0.04-2.53)
2.34 (1.06-5.19)
0.784
0.417
0.030
0.148
0.439
0.049   3.79 (0.97-14.85) 0.056
Data are presented as number (%) of patients unless otherwise specified. *Hazard ratio for all-cause mortality. TB, tuberculosis; MDR-TB,multidrug-resistant tuberculosis; XDR-
TB,extensively drug-resistant tuberculosis.Jeon DS, et al.  •  MDR-TB in the Public Sector of Korea
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All-cause mortality and its predictors
Nine patients died during treatment and additional 54 died dur-
ing the 3-4 yr of follow-up after treatment initiation, thus all-cause 
mortality rate was 31.2% (63/202) during the study period. The 
median survival time of patients previously treated with second-
line drugs was significantly shorter than that of new patients (P < 
0.001) and patients previously treated with first-line drugs (P = 
0.003) (Fig. 2). The median survival time of patients with XDR-
TB was significantly shorter than that of patients with non-XDR-
TB (P = 0.002).
  The results of univariate analysis for predictors of all-cause 
mortality are shown in Table 4. Independent predictors of all-
cause mortality were age (aHR, 1.04; 95% CI, 1.01-1.07; P = 0.006), 
XDR-TB (aHR, 13.42; 95% CI, 2.98-60.53; P = 0.001), history of 
MDR-TB treatment (aHR, 2.21; 95% CI, 1.03-4.72, P = 0.042), and 
resistance to prothionamide (aHR, 3.10; 95% CI, 1.05-9.11; P = 
0.040). 
DISCUSSION
This study showed poor outcome for patients with MDR-TB at 
the 3 TB hospitals in Korea: low treatment success rate (37.1%), 
high default rate (37.1%), and high all-cause mortality rate (31.2 
%) during the 3-4 yr after treatment initiation. This result reflects 
the current status of MDR-TB in the public sector of Korea. 
  In Korea, the prevalence of TB has decreased markedly since 
the establishment of NTP in 1962 (9). However, the rate of de-
crease of TB prevalence has slowed, and MDR-TB has emerged 
as a significant threat to public health in the 2000s (10, 11). The 
proportion of MDR-TB among new TB cases increased from 
1.6% in 1994 to 2.7% in 2004 (12). Furthermore, Korea has be-
come known as a country with high prevalence of XDR-TB (13). 
Since the NTP of Korea has focused on new cases, there have 
been limited nationwide data about the incidence and preva-
lence of MDR-TB and its treatment outcomes. 
  Treatment success rate of our study is the lowest ever report-
ed among MDR-TB cohorts in Korea. Treatment success rates of 
MDR-TB in Korea vary depending on the study sites, range from 
44.1% to 66.0% (6, 14-17). It is difficult to determine the current 
status of MDR-TB in Korea from these studies, since most had a 
small number of subjects from single institute, different study 
designs, or different definitions of treatment outcomes. Kim et al. 
(6) reported the treatment outcomes of 1,407 patients with MDR-
TB from 2000 to 2002 in Korea and showed slightly better out-
comes than those in our study: 45.3% treatment success rate and 
32.2% default rate. The study of Kim et al. is significant for the 
following reasons. First, the study was conducted on a large num-
bers of subjects from both the public and private sector. There-
fore, it might be more closely reflect the real status of MDR-TB 
in Korea. Second, their results could be comparable with those 
in other countries, since the authors mostly followed WHO’s 
recommended cohort analysis. The design of our study was al-
most the same as that of the study of Kim et al. (6), because we 
wanted to compare the outcomes by using same definitions. 
  The treatment success rates of other countries have been re-
ported to be about 62% in 2 meta-analyses (18, 19). The majori-
ty of countries included in these meta-analyses had well-estab-
lished TB control programs such as DOTS (directly observed 
treatment, short-course)-Plus. This success rate could be a fea-
sible target in Korea if we learn from the experiences of other 
countries. 
  The poor outcome in our study is probably related to the high 
default rate. The default rate in our study was 37.1%, which 
comprised 59.1% of the poor outcomes. Although it is generally 
Fig. 2. Kaplan-Meier estimates of survival for 202 patients with multidrug-resistant tuberculosis: (A) all-cause mortality according to previous treatment history (P = 0.032 for 
a vs b, P = < 0.001 for a vs c, P = 0.003 for b vs c, respectively) and (B) all-cause mortality between XDR-TB and non-XDR-TB (P = 0.002). XDR-TB, extensively drug-resistant 
tuberculosis.
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thought that the default rate is higher in the private sector (20), 
the default rate in our study was not very different from that in 
the private sector. In the 3 TB hospitals, a nurse or case manager 
calls patients who default, but this approach allows the tracking 
of patients only to a limited extent. Default is an issue of MDR-
TB management worldwide, but the rate is especially high in 
Korea, ranging from 3.3% to 39.0% (6, 14-17). The average de-
fault rates in other countries have been reported to be 12%-13% 
(18, 19). High default rates in Korea suggest that the NTP is not 
effective against MDR-TB.
  The lower success rate in our study, compared with other stud-
ies in Korea, might be related to a referral bias. The study sites 
were TB referral hospitals where patients with more severe dis-
ease, more comorbidities, and lower socioeconomic status were 
transferred. In our study, 70.1% of patients had far advanced 
disease, 36.1% had previously failed to second-line agents, and 
47.5% had ofloxacin-resistant strains. Moreover, difference in 
treatment strategies might influence treatment outcomes. Ad-
junctive surgical resection is known to be an independent pre-
dictor of treatment success (6, 17, 21), but surgical treatment was 
performed in only 4.0% (8/202) of patients in our study. Further 
multi-center study including both the private and public sector 
is needed to clarify the exact reasons for poor outcome in this 
study. 
  Inadequate treatment of MDR-TB necessarily results in high 
mortality and the development of XDR-TB (22), as shown in this 
study. Independent predictors of poor outcome were male sex, 
positive smear at treatment initiation, and XDR-TB, which have 
already been shown to be factors associated with worse outcomes 
in a meta-analysis (19). XDR-TB was an independent predictor 
of both poor outcome and all-cause mortality as in the study of 
Kim et al. (6). XDR-TB is thought to developed and spread due 
to inappropriate treatment with second-line drugs and lack of 
adequate infection-control programs. Therefore, XDR-TB is the 
indicator of inadequate TB control program (23). In this study, 
the proportion of XDR-TB among new cases was high (17.1%), 
which suggests that the spread of XDR-TB is presently a serious 
public health problem in Korea. 
  Considering the current poor outcomes of MDR-TB, the NTP 
of Korea should be reevaluated. Comprehensive and aggressive 
treatment strategies improved treatment outcomes of MDR/
XDR-TB (24-26). A comprehensive TB control program should 
include socioeconomic support, an adequate follow-up system, 
an infection control program, and careful management of co-
morbidities, as well as proper case management. DOT is be-
lieved to prevent the emergence of drug-resistant TB and has 
been the essential component of NTP worldwide, since its es-
tablishment in 2004 by the WHO (27). Orensteun et al. (18) re-
ported a meta-analysis showing that MDR-TB treatments for 
more than 18 months and DOT through the entire treatment 
period are independent predictors of treatment success. DOT is 
presently conducted in 180 countries (28), but it is not conduct-
ed in Korea. Furthermore, social economic support and careful 
management of comorbidities, such as alcoholism, are other 
strategies to improve the treatment success rate of TB (24, 29). 
The lack of such comprehensive strategies, including DOT, might 
be related to the poor outcomes of MDR-TB in Korea. Although 
the government of Korea has provided partial support for the 
medical costs of MDR-TB patients since 2007, more comprehen-
sive management strategy should be integrated into the NTP. 
  This study has several limitations. First, DSTs were performed 
in each hospital separately and the qualities of DSTs were not 
strictly controlled despite their own internal and external quali-
ty control program. Second, since DST for amikacin, capreomy-
cin, and other fluroquinolones except ofloxacin were not per-
formed, actual number of XDR-TB patients might be underesti-
mated. Third, HIV-ELISA tests were performed on only 2 patients. 
Since Korea has been a low HIV-burden country with a report-
ed prevalence below 0.1% (30), the results of our study might 
reflect that of non-HIV-infected patients with MDR-TB. Despite 
these limitations, our study is the first study which shows the 
status of MDR-TB in tuberculosis hospitals in the public sector 
of Korea.  
  In conclusion, the treatment outcomes of patients with MDR-
TB at the 3 TB hospitals are poor, which may reflect the current 
status of MDR-TB in the public sector of Korea. A more compre-
hensive program against MDR-TB needs to be integrated into 
the NTP of Korea. 
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This study was conducted to evaluate treatment outcome, mortality, and predictors of both in patients with multidrug-resistant 
tuberculosis (MDR-TB) at 3 TB referral hospitals in the public sector of Korea. We included MDR-TB patients treated at 3 TB referral 
hospitals in 2004 and reviewed retrospectively their medical records and mortality data. Of 202 MDR-TB patients, 75 (37.1%) had 
treatment success and 127 (62.9%) poor outcomes. Default rate was high (37.1%, 75/202), comprising 59.1% of poor outcomes. 
Male sex (adjusted odds ratio [aOR], 2.91; 95% confidence interval [CI], 1.13-7.49), positive smear at treatment initiation (aOR, 
5.50; 95% CI, 1.22-24.90), and extensively drug-resistant TB (aOR, 10.72; 95% CI, 1.23-93.64) were independent predictors of 
poor outcome. The all-cause mortality rate was 31.2% (63/202) during the 3-4 yr after treatment initiation. In conclusion, the 
treatment outcomes of patients with MDR-TB at the 3 TB hospitals are poor, which may reflect the current status of MDR-TB in 
the public sector of Korea. A more comprehensive program against MDR-TB needs to be integrated into the National Tuberculosis 
Program of Korea.